A study, published in BMC Biotechnology, reports on a new vaccine production method which may make storage and transport easier.
Prof Jimmy Whitworth, Professor of International Public Health, London School of Hygiene & Tropical Medicine (LSHTM), said:
“There are some encouraging aspects to this paper, although it provides mainly preliminary findings, and is not, at this stage, definitive.
“The production method is simple, likely to be at a low cost and does not require the use of an adjuvant (an ingredient used in some vaccines that helps create a stronger immune response).
“The vaccine is stable at ‘ambient temperature’ although the actual temperature does not seem to be specified. This could be valuable if it means that a cold chain is not needed. The stability findings are peculiar – it seems to be stable at low temperatures (-20oC and below) and at room temperatures, but not at 4oC, which is the temperature of an ordinary fridge. It would be good to know if it is stable at the sort of temperatures encountered in low and middle income countries – ie. around 20-40oC.
“The vaccine induced robust immune responses in mice that persisted for 6 months.
“So, all in all, promising, and definitely worth following up to demonstrate its stability at relevant temperatures, that it works with a variety of vaccine constructs, and that it induces immune responses in humans.”
‘A self-aggregating peptide: implications for the development of thermostable vaccine candidates’ by Cruz-Reséndiz et al. was published in BMC Biotechnology.
Prof Jimmy Whitworth: “No conflicts to declare.”